CHIMENTI, SERGIO
 Distribuzione geografica
Continente #
NA - Nord America 2.457
EU - Europa 2.204
AS - Asia 997
AF - Africa 78
SA - Sud America 70
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 7
Totale 5.861
Nazione #
US - Stati Uniti d'America 2.342
DE - Germania 722
IT - Italia 456
IN - India 274
CN - Cina 159
GB - Regno Unito 159
FR - Francia 151
KR - Corea 88
IE - Irlanda 79
CA - Canada 75
ES - Italia 75
JP - Giappone 69
RU - Federazione Russa 67
TR - Turchia 60
NL - Olanda 59
ID - Indonesia 50
AU - Australia 44
RO - Romania 44
VN - Vietnam 44
UA - Ucraina 42
GR - Grecia 41
SE - Svezia 33
MX - Messico 31
CH - Svizzera 30
EG - Egitto 30
PL - Polonia 29
CZ - Repubblica Ceca 25
MY - Malesia 25
PH - Filippine 25
DK - Danimarca 23
IQ - Iraq 23
PT - Portogallo 23
BR - Brasile 22
HU - Ungheria 22
SG - Singapore 22
FI - Finlandia 20
PK - Pakistan 20
ZA - Sudafrica 18
CL - Cile 17
TH - Thailandia 17
SA - Arabia Saudita 16
HK - Hong Kong 15
NO - Norvegia 15
AE - Emirati Arabi Uniti 14
AT - Austria 12
HR - Croazia 12
IR - Iran 12
BE - Belgio 11
LT - Lituania 11
PE - Perù 11
TW - Taiwan 11
AR - Argentina 10
IL - Israele 10
BD - Bangladesh 9
LB - Libano 7
LV - Lettonia 7
EC - Ecuador 6
SK - Slovacchia (Repubblica Slovacca) 6
BG - Bulgaria 5
EE - Estonia 5
ET - Etiopia 5
JO - Giordania 5
SI - Slovenia 5
GH - Ghana 4
LK - Sri Lanka 4
MG - Madagascar 4
NZ - Nuova Zelanda 4
RS - Serbia 4
TN - Tunisia 4
AP - ???statistics.table.value.countryCode.AP??? 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
DZ - Algeria 3
EU - Europa 3
GE - Georgia 3
MK - Macedonia 3
MM - Myanmar 3
BH - Bahrain 2
CO - Colombia 2
GN - Guinea 2
GT - Guatemala 2
KW - Kuwait 2
LU - Lussemburgo 2
MO - Macao, regione amministrativa speciale della Cina 2
NP - Nepal 2
SO - Somalia 2
A1 - Anonimo 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BJ - Benin 1
BY - Bielorussia 1
CM - Camerun 1
DO - Repubblica Dominicana 1
ER - Eritrea 1
HN - Honduras 1
HT - Haiti 1
MA - Marocco 1
ME - Montenegro 1
MU - Mauritius 1
OM - Oman 1
Totale 5.855
Città #
Woodbridge 474
Houston 318
Ann Arbor 118
Fairfield 117
Wilmington 102
Ashburn 93
Santa Cruz 87
Buffalo 79
Dublin 69
Seattle 67
Cambridge 56
Rome 56
Delhi 55
Nürnberg 55
Beijing 48
University Park 43
Milan 38
Mountain View 38
Hyderabad 31
Jakarta 24
Mumbai 23
New York 22
Bengaluru 21
Toronto 21
Dong Ket 20
Duncan 20
Hangzhou 20
London 20
Leawood 18
Tokyo 18
Stockholm 17
Hanoi 15
Las Vegas 15
Paris 15
San Diego 15
Wuhan 15
Athens 14
Los Angeles 14
Boston 13
Ottawa 13
Sydney 13
Cairo 12
Helsinki 12
Boardman 11
Chennai 11
Chicago 11
Istanbul 11
Naples 11
New Delhi 11
Padova 11
Phoenix 11
Utrecht 11
Herndon 10
Lima 10
Madrid 10
Bucharest 9
Changsha 9
Gurgaon 9
Kuala Lumpur 9
Shanghai 9
Verona 9
Bangalore 8
Bangkok 8
Bend 8
Berlin 8
Guangzhou 8
Muizenberg 8
Saint Petersburg 8
Singapore 8
Ankara 7
Budapest 7
Ciudad Real 7
Dubai 7
Napoli 7
Riyadh 7
San Francisco 7
Warsaw 7
Bergen 6
Bologna 6
Charlottesville 6
Clearwater 6
Dallas 6
Edmonton 6
Hamburg 6
Izmir 6
Kiev 6
Polska 6
Pune 6
Quito 6
Rotterdam 6
Ulm 6
Amsterdam 5
Basra 5
Brooklyn 5
Copenhagen 5
Genoa 5
Johannesburg 5
Lake Forest 5
Munich 5
Newbury Park 5
Totale 2.786
Nome #
European S3-guidelines on the systemic treatment of psoriasis vulgaris, file e291c0d4-3aae-cddb-e053-3a05fe0aa144 1.540
Treatment of lentigo maligna with tazarotene 0.1% gel, file e291c0d4-3f96-cddb-e053-3a05fe0aa144 815
Clinical severity instruments, file e291c0d8-dea0-cddb-e053-3a05fe0aa144 689
Prevention of Dermatologic Side Effects of Bimatoprost 0.03% Topical Therapy, file e291c0d4-5237-cddb-e053-3a05fe0aa144 598
Efalizumab, file e291c0d8-2a04-cddb-e053-3a05fe0aa144 412
The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice, file e291c0d5-b29f-cddb-e053-3a05fe0aa144 399
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment, file e291c0d4-7d0b-cddb-e053-3a05fe0aa144 336
Reply to Scalone and Cortesi: ‘‘Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs’’, file e291c0d5-b233-cddb-e053-3a05fe0aa144 245
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma, file e291c0d5-e36c-cddb-e053-3a05fe0aa144 216
Ichthyosiform mycosis fungoides: A neoplastic acquired ichthyosis [5], file e291c0d5-c2be-cddb-e053-3a05fe0aa144 210
Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B [10], file e291c0d5-f270-cddb-e053-3a05fe0aa144 209
Long-lasting remission of pemphigus vulgaris treated with rituximab, file e291c0d5-e480-cddb-e053-3a05fe0aa144 158
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody, file e291c0d5-f300-cddb-e053-3a05fe0aa144 156
The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practic Settings in Italy, file e291c0d5-a854-cddb-e053-3a05fe0aa144 110
Quality of life in patients with plaque psoriasis treated with biologic therapies, file e291c0d5-aee6-cddb-e053-3a05fe0aa144 75
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up, file e291c0d8-bc54-cddb-e053-3a05fe0aa144 3
Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients, file e291c0d5-43ab-cddb-e053-3a05fe0aa144 2
Clinical aspects of the oral cavity in patients with psoriasis: an initial study and a proposal of a new evaluation method, file e291c0d5-7dee-cddb-e053-3a05fe0aa144 2
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene, file e291c0d5-f16e-cddb-e053-3a05fe0aa144 2
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis, file e291c0d8-ba82-cddb-e053-3a05fe0aa144 2
Phrynoderma: a cutaneous sign of an inadequate diet, file e291c0d5-3fb2-cddb-e053-3a05fe0aa144 1
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy, file e291c0d5-43b4-cddb-e053-3a05fe0aa144 1
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice, file e291c0d5-4696-cddb-e053-3a05fe0aa144 1
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers, file e291c0d5-6665-cddb-e053-3a05fe0aa144 1
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers, file e291c0d5-68c7-cddb-e053-3a05fe0aa144 1
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis, file e291c0d5-d8eb-cddb-e053-3a05fe0aa144 1
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study, file e291c0d5-dacb-cddb-e053-3a05fe0aa144 1
Remission and time of resolution of nail psoriasis during infliximab therapy [27], file e291c0d6-139b-cddb-e053-3a05fe0aa144 1
Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: an open, prospective study [9], file e291c0d6-191c-cddb-e053-3a05fe0aa144 1
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases, file e291c0d6-1c22-cddb-e053-3a05fe0aa144 1
Pyoderma vegetans and ulcerative colitis, file e291c0d6-1dad-cddb-e053-3a05fe0aa144 1
Influence and variation of the body mass index in patients treated with etancercept for psoriasis, file e291c0d6-1db6-cddb-e053-3a05fe0aa144 1
Green sweating spots on hands and feet: unusual expression of hyperbilirubinemia, file e291c0d6-1ed9-cddb-e053-3a05fe0aa144 1
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study, file e291c0d6-bba6-cddb-e053-3a05fe0aa144 1
Zosteriform metastasis of occult bronchogenic carcinoma, file e291c0d7-19bf-cddb-e053-3a05fe0aa144 1
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey, file e291c0d7-31e8-cddb-e053-3a05fe0aa144 1
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris, file e291c0d8-9787-cddb-e053-3a05fe0aa144 1
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases, file e291c0d8-bc50-cddb-e053-3a05fe0aa144 1
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis, file e291c0d8-bc52-cddb-e053-3a05fe0aa144 1
Linear psoriasis following the typical distribution of the sciatic nerve, file e291c0d8-bc58-cddb-e053-3a05fe0aa144 1
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome, file e291c0d8-eb66-cddb-e053-3a05fe0aa144 1
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis, file e291c0d8-eb6a-cddb-e053-3a05fe0aa144 1
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab, file e291c0d8-eec4-cddb-e053-3a05fe0aa144 1
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis, file e291c0d8-eec9-cddb-e053-3a05fe0aa144 1
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab, file e291c0d9-0282-cddb-e053-3a05fe0aa144 1
Long-term efficacy of adalimumab in generalized pustular psoriasis, file e291c0d9-0285-cddb-e053-3a05fe0aa144 1
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry, file e291c0d9-045d-cddb-e053-3a05fe0aa144 1
Totale 6.206
Categoria #
all - tutte 8.984
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.984


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019298 0 0 0 0 0 0 0 0 0 73 112 113
2019/2020817 102 85 47 79 74 64 55 40 74 62 64 71
2020/2021817 51 73 69 57 92 57 58 76 69 87 62 66
2021/20221.131 73 74 77 157 129 57 79 69 94 65 164 93
2022/20231.080 86 66 175 132 91 156 93 58 60 58 66 39
2023/2024512 46 63 57 47 54 48 42 65 58 32 0 0
Totale 6.206